U.S. Markets open in 7 hrs 7 mins

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.49+0.10 (+1.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.39
Open7.07
Bid0.00 x 3100
Ask0.00 x 900
Day's Range6.98 - 7.51
52 Week Range2.30 - 24.57
Volume1,427,929
Avg. Volume4,096,651
Market Cap586.943M
Beta (5Y Monthly)0.74
PE Ratio (TTM)325.65
EPS (TTM)0.02
Earnings DateMay 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 28, 2014
1y Target Est23.60
  • Why Veru (VERU) Might Surprise This Earnings Season
    Zacks

    Why Veru (VERU) Might Surprise This Earnings Season

    Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?

    Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients
    Benzinga

    Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients

    Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of patients who have failed estrogen blocking agents and CDK 4/6 inhibitors. Data will be presented at the European Society for Medical Oncology Breast Cancer Virtual Congress 2021. The subset of patients includes those who were heavily pretreated with estrogen-blocking agents and chemotherapy with an average of 3 prior lines of therapy in the metastatic setting and had tumor progression on a CDK 4/6 inhibitor before receiving enobosarm. Enobosarm treatment in evaluable patients who had progressed following treatment with an estrogen-blocking agent and CDK 4/6 inhibitor (palbociclib) resulted in a clinical benefit rate at 24 weeks of 50% and a best objective tumor response of 30%, including two complete responses and one partial response. The overall mean radiographic progression-free survival for the 9mg dose was ten months. The 9mg dose of enobosarm was selected for the Phase 3 ARTEST study anticipated to start in June. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor, tumor suppressor, in AR+ER+HER2- metastatic breast cancer. Price Action: VERU stock moved 26.4% higher at $11 during the premarket trading session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaNeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For 0MChiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.